SCHEMBL6919031

SCHEMBL6919031

CN(c1cncnc1)c1cc(F)cc(C(=O)Nc2nccs2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.69
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
BRD4 O60885 1/20 0.46
MAPT P10636 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
AGER Q15109 1/20 0.46
GCK P35557 1/20 0.44
CYP3A4 P08684 1/20 0.44
DRD3 P35462 1/20 0.44
SLC6A3 Q01959 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6919092 0.89 GRM5 (0.55) GRM5SMN1; SMN2RAB9ANPC1AGER
SCHEMBL6918581 0.87 GRM5 (0.59) GRM5SMN1; SMN2RAB9ANPC1BRD4
SCHEMBL6918568 0.83 MEN1 (0.59) GRM5SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL1979922 0.82 GRM5 (1.00) GRM5SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL12601821 0.80 GRM5 (0.71) GRM5SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6918502 0.80 GRM5 (0.71) GRM5RAB9ANPC1CYP3A4DRD3
SCHEMBL8797043 0.79 RAB9A (0.62) SMN1; SMN2RAB9ANPC1BRD4MAPT
SCHEMBL6918313 0.78 GRM5 (0.60) GRM5CYP3A4KDM4E
SCHEMBL6918104 0.78 GRM5 (0.67) GRM5GCKCYP3A4DRD3SLC6A3
SCHEMBL6918192 0.77 GRM5 (0.59) GRM5RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796295-B2 Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same VANDERBILT UNIVERSITY (US) 2014-08-05 US disclosed
US-20110152299-A1 SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-06-23 US disclosed
WO-2011035209-A1 SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME VANDERBILT UNIVERSTIY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152299-A1 SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME GRM5, GRIK5, GRIN2A GRM5 1/4885SMN1; SMN2 1565/4885RAB9A 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.